top of page

Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more

  • blonca9
  • Aug 9, 2024
  • 1 min read

Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE phase 3 readout, the rational for myostatin inhibition in obesity, and recent ASCO data.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page